<DOC>
	<DOCNO>NCT03083990</DOCNO>
	<brief_summary>To confirm PK similarity IBI305 bevacizumab healthy volunteer .</brief_summary>
	<brief_title>Compare IBI305 Bevacizumab Pharmacokinetics/Safety/Immunogenicity Healthy Male</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>To eligible study , patient fulfill follow criterion : 1 . Fully understand study purpose , understand pharmacological effect potential adverse reaction drug , voluntarily sign write informed consent accord declaration Helsinki . 2 . Age ≥18 ≤ 50 , healthy male subject 3 . Weigh ≥ 50 kg ≤ 100 kg， BMI≥ 19 ≤ 28 kg/m2 4 . All system test result within normal range , abnormal test result without clinical significance judge investigator . 5 . The subject must agree use effective contraceptive measure study treatment 6 month receive last study drug ( e.g . abstinence , sterilization surgery , oral contraceptive , contraception progesterone injection subcutaneous ) Patients enter study follow exclusion criterion fulfil : 1 . Medical history high blood pressure abnormal blood pressure screening/baseline ( Double confirm systolic blood pressure ( SBP ) &gt; 140 mmHg and/or diastolic blood pressure ( DBP ) &gt; 90 mmHg within one day ) 2 . Proteinuria clinical significance judge investigator ( routine urine examination , urine protein 2 + ) history proteinuria . 3 . Any prior VEGF ( vascular endothelial growth factor ) VEGFR ( Vascular Endothelial Growth Factor Receptor ) antibody protein treatment within one year . 4 . Any biological product live virus vaccine treatment within 3 month , monoclonal antibody within 12 month first dose study drug . 5 . History evidence inherit bleed diathesis coagulopathy thrombus . 6 . History digestive tract perforation digestive tract fistula . 7 . Serious , nonhealing wound , active ulcer , untreated bone fracture , major surgical procedure within 2 month prior randomization anticipation need major surgery course study 2 month last dose study drug . 8 . Use Rx OTC drug nutritional health product within 5 halflives within 2 week first dose study drug ( According long time ) .Herbal supplement need stop 28 day first dose study drug . 9 . Positive hepatitis b surface antigen ( HBsAg ) , hepatitis c virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody syphilis 10 . Known hypersensitivity Bevacizumab excipients 11 . Known allergic disease allergic constitution 12 . History blood donation within 3 month first dose study drug 13 . Treatment investigational agent participation another clinical trial within 3 month prior screen 14 . History alcoholism drug abuse within 12 month prior screen ; Subjects temperance within 72 hour study drug infusion whole study 15 . History mental illness 16 . Anticipated partner pregnancy study . 17 . Incompliance clinical study protocol study . 18 . Other condition investigator think unsuitable study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>